QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
QQQ   445.61 (+1.51%)
AAPL   179.66 (-0.60%)
MSFT   415.50 (+0.45%)
META   502.30 (+2.48%)
GOOGL   137.14 (-0.95%)
AMZN   178.22 (+0.83%)
TSLA   202.64 (+0.38%)
NVDA   822.79 (+4.00%)
NIO   5.77 (+0.35%)
AMD   202.64 (+5.25%)
BABA   74.63 (+0.81%)
T   17.00 (+0.41%)
F   12.45 (+0.08%)
MU   95.15 (+5.01%)
CGC   3.21 (-2.43%)
GE   158.67 (+1.13%)
DIS   111.93 (+0.31%)
AMC   4.36 (+0.93%)
PFE   26.58 (+0.08%)
PYPL   60.54 (+0.33%)
XOM   105.78 (+1.21%)
NASDAQ:CDTX

Cidara Therapeutics (CDTX) Stock Price, News & Analysis

$0.71
0.00 (0.00%)
(As of 03/1/2024 ET)
Today's Range
$0.70
$0.74
50-Day Range
$0.64
$0.82
52-Week Range
$0.59
$2.10
Volume
238,173 shs
Average Volume
485,068 shs
Market Capitalization
$64.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.67

Cidara Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
555.2% Upside
$4.67 Price Target
Short Interest
Healthy
0.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
1.44mentions of Cidara Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.28) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.21 out of 5 stars

Medical Sector

164th out of 957 stocks

Biological Products, Except Diagnostic Industry

20th out of 160 stocks


CDTX stock logo

About Cidara Therapeutics Stock (NASDAQ:CDTX)

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CDTX Stock Price History

CDTX Stock News Headlines

Bezos and Gates Invest in Search for Tech's Best-Kept Secret
Billionaires who've made their fortunes in tech, are quietly investing in essential yet rare elements known as "The Seeds of Technology". Learn more about this massive rare earth treasure hunt and the very elements making emerging technologies possible.
Cidara Therapeutics Granted Nasdaq Listing Extension
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
See More Headlines
Receive CDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/01/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CDTX
Fax
N/A
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.67
High Stock Price Target
$6.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+546.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-29,800,000.00
Pretax Margin
-53.14%

Debt

Sales & Book Value

Annual Sales
$64.29 million
Book Value
($0.04) per share

Miscellaneous

Free Float
84,755,000
Market Cap
$65.28 million
Optionable
Optionable
Beta
0.93
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Jeffrey L. Stein Ph.D. (Age 69)
    President, CEO & Executive Director
    Comp: $873.25k
  • Dr. Preetam Shah M.B.A. (Age 51)
    Ph.D., CFO, Chief Business Officer & Principal Accounting Officer
    Comp: $577.85k
  • Dr. Taylor Sandison (Age 52)
    Chief Medical Officer
    Comp: $632.05k
  • Dr. Kevin M. Forrest Ph.D. (Age 47)
    Founder and Chief Strategy Officer
    Comp: $333.31k
  • Mr. Shane M. Ward (Age 49)
    COO & Chief Legal Officer
  • Ms. Allison Lewis CCP
    SPHR, Senior Vice President of People & Culture
  • Dr. Leslie Tari Ph.D. (Age 57)
    Chief Scientific Officer
    Comp: $845.1k
  • Ms. Laura A. Navalta
    Senior Vice President of Clinical Operations
  • Dr. Nicole Davarpanah J.D.
    M.D., Senior VP of Translational Research & Development














CDTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Cidara Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDTX shares.
View CDTX analyst ratings
or view top-rated stocks.

What is Cidara Therapeutics' stock price target for 2024?

3 brokers have issued twelve-month price targets for Cidara Therapeutics' stock. Their CDTX share price targets range from $3.00 to $6.00. On average, they expect the company's share price to reach $4.67 in the next year. This suggests a possible upside of 555.2% from the stock's current price.
View analysts price targets for CDTX
or view top-rated stocks among Wall Street analysts.

How have CDTX shares performed in 2024?

Cidara Therapeutics' stock was trading at $0.7940 at the beginning of the year. Since then, CDTX stock has decreased by 10.3% and is now trading at $0.7122.
View the best growth stocks for 2024 here
.

Are investors shorting Cidara Therapeutics?

Cidara Therapeutics saw a decrease in short interest in the month of February. As of February 15th, there was short interest totaling 463,300 shares, a decrease of 22.1% from the January 31st total of 594,500 shares. Based on an average daily volume of 673,200 shares, the days-to-cover ratio is presently 0.7 days.
View Cidara Therapeutics' Short Interest
.

When is Cidara Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our CDTX earnings forecast
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) issued its earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.01. The biotechnology company had revenue of $7.08 million for the quarter, compared to analyst estimates of $3.62 million. Cidara Therapeutics had a negative net margin of 55.49% and a negative trailing twelve-month return on equity of 264.84%.

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Who are Cidara Therapeutics' major shareholders?

Cidara Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.70%), Nantahala Capital Management LLC (1.71%), GSA Capital Partners LLP (0.60%), Northern Trust Corp (0.18%), Virtu Financial LLC (0.11%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Brady Johnson, Jeffrey Stein, Jessica Oien, Leslie Tari, Neil Abdollahian, Paul Daruwala, Preetam Shah, Shane Ward, Taylor Sandison and Timothy R Franson.
View institutional ownership trends
.

How do I buy shares of Cidara Therapeutics?

Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDTX) was last updated on 3/1/2024 by MarketBeat.com Staff